Asthma

This study demonstrated the long-term efficacy of mepolizumab, a monoclonal interleukin-5 antibody, in reducing asthma exacerbations, steroid dependence, and nasal polyps over a 3-year period. Mepolizumab (MEP) is a monoclonal antibody that acts against interleukin (IL)-5 to control the proliferation, maturation, and activity of eosinophils. The efficacy of MEP in patients with severe asthma has...

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on August 3, 2023 Regular exercise for 6 months reduces the regular inhaled corticosteroid dose without limiting asthma. Inhaled corticosteroids (ICS) are the primary form of asthma treatment currently in use. These powerful anti-inflammatory drugs improve asthma control, maintain lung function, and prevent exacerbations by reducing airway...

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on August 3, 2023 Compared to a written action plan alone, a digital action plan was used less frequently and did not affect the number of unscheduled medical contacts in this study. One strategy for managing asthma symptoms is a patient-tailored asthma action plan, including self-management instructions....

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on August 3, 2023 Atopic dermatitis increases the risk of asthma and other allergy-related symptoms. Other atopic and allergy conditions are also common. This includes asthma (10–30% of cases), food allergies, allergic rhinitis, allergic conjunctivitis, and eosinophilic disorders. This narrative review, published in the Asian Pacific Journal...

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on August 3, 2023 An open-label placebo alleviated seasonal allergy symptoms, whereas a conventional placebo had no effect. Allergic rhinitis symptoms fluctuate with seasonal allergen levels. There is evidence that placebos are effective as symptomatic treatments. New research challenges the idea that placebo effects need deception by...

Dupilumab is a human monoclonal antibody that mediates improvement in the clinical outcomes of patients diagnosed with moderate-to-severe type 2 asthma, regardless of the status of allergen sensitization. Dupilumab is defined as a human monoclonal antibody that is implicated in different type-2 anti-inflammatory diseases. The previous study demonstrated that dupilumab decreased severe asthma exacerbation and...

This study demonstrates the association between greater odds of asthma attacks in the previous 12 months and higher concentrations of PFDA and PFOA in the serum, which was significant for individuals aged 12 to 18 years. Per- and poly-fluoroalkyl substances (PFAS) are chemicals widely utilized in manufacturing and tend to be highly resistant to degradation;...

This cross-sectional study demonstrated a positive association between the prevalence of asthma and results for the Metabolic Score for Visceral Fat index; however, the relationship is non-linear. There is a negative correlation trend between the prevalence of asthma and the METS-VF index of less than 5.24. The Metabolic Score for Visceral Fat (METS-VF) estimation tool...

Length of stay is one way to measure how severely an illness affects a population. This study analyzes length of stay disparities in several pediatric illnesses, including asthma. Inequities in the quality of care for pediatric illnesses have historically impacted marginalized races and ethnicities in a negative way. Among the many metrics that can be...